US' HDT Bio Corp. begins Phase I/II trial of COVID-19 vaccine in India
Image Credit: shortpedia
US-based biopharmaceutical company HDT Bio Corp., a developer of immunotherapies for oncology and infectious diseases, has announced to begin Phase I/II trial of its COVID-19 vaccine in India. The Phase I/II trial of the vaccine developed by HDT Bio in partnership with Gennova Biopharmaceuticals in India is expected to be an affordable one as compared to the existing vaccines in the west.